
A recent study examined the impact of revised response criteria (IWG2023) on prognosis in higher-risk myelodysplastic syndromes (HR-MDS) patients treated with azacitidine. The study found that the new criteria, particularly the lowered hemoglobin cutoff value, provided better prognosis prediction compared to the older IWG2006 criteria. However, additional research with larger patient populations is needed to validate these findings and assess the significance of other criteria changes. This study underscores the importance of accurate response classification for treatment outcomes in HR-MDS patients.
Like
Save
Share